By New Scientist
June 7, 2012
Last week a new vaccine for Parkinson's was trialed on 32 people. The vaccine aims to destroy alphasynuclein, a protein believed to trigger the disease by messing up dopamine levels, "When it forms clumps in cells, alpha-synuclein disrupts normal levels of dopamine by locking it inside cells that produce it. It is also toxic, killing neurons and their connections," says Mandler Markus, a scientist who's part of the trial. This is an entirely new approach because most treatments just aim to boost dopamine levels instead of actually fixing the problem.
No comments:
Post a Comment